Phase 2a Trial of Riluzole for Cancer-Related Cognitive Impairment Initiated
A phase 2a pilot trial is underway to assess riluzole's effects on BDNF levels in cancer survivors with cognitive impairment.
Phase III
cancer survivors
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of a phase 2a trial for riluzole in treating cognitive impairment in cancer survivors is significant as it explores a novel therapeutic avenue in a largely underserved area. Positive outcomes could enhance riluzole's market positioning and broaden its clinical applications, impacting treatment paradigms in oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and BDNF level changes, as well as any subsequent studies or interest from other companies in this indication.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.